MediciNova completes patient enrollment in neuropathy trial of MN-166

MediciNova (MNOV) completed patient enrollment in the Phase 2 clinical trial, the OXTOX study – Oxaliplatin Neurotoxicity study in patients with metastatic colorectal cancer -. This study is evaluating MN-166 – ibudilast – for the prevention of chemotherapy-induced peripheral neuropathy in patients with metastatic colorectal cancer. A total of 100 patients have been randomized across two treatment arms at 11 clinical sites in Australia. Patient recruitment is now officially closed. Study participants will continue chemotherapy along with the assigned study drug, MN-166 or placebo, until disease progression or unacceptable side effects. The study will conclude when the final patient reaches six months post-chemotherapy. While the exact study completion date is not yet determined, the company anticipates that top-line data may be available later in 2026. For the amyotrophic lateral sclerosis indication, MediciNova has Orphan Drug Designation& Fast Track Status from the FDA and Orphan Drug Designation from the EMA.